Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2021-06-16
Target enrollment:
Participant gender:
Summary
Men with progressive metastatic Castration-Resistant Prostate Cancer post first-line
treatment with either androgen deprivation therapy alone or androgen deprivation therapy plus
docetaxel who have an identified related female donor (mother sister, daughter, second degree
relative such as granddaughter or niece) will undergo bone marrow transplantation followed by
post-transplant Cytoxan (PT/Cy) and testosterone.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins